Alzheimer's Drug Faces Scrutiny Over Safety, Efficacy Concerns

The FDA-approved Alzheimer's drug donanemab is under scrutiny due to concerns about its effectiveness and safety, according to an investigation. The study highlights multiple patient deaths during trials, design flaws, and the financial ties of panelists who recommended the drug's approval.